中国经济网北京9月15日讯 复星医药（600196.SH）13日发布关于为控股子公司提供担保的进展 公告。截至2025年9月12日，包括本次担保在内，集团实际对外担保金额折合人民币约2,360,240万 元，约占2024年12月31日集团经审计的归属于上市公司股东净资产的49.94%；均为公司与控股子公 司/单位之间、控股子公司/单位之间发生的担保。 | 对外担保逾期的累计金额 | 人民币 0元 | | --- | --- | | 截至2025年9月12日,包括本次担保在 内,本集团实际对外担保金额 | 折合人民币约 2,360,240万元 | | 对外担保金额占 2024年12月 31 日 本集团经审计净资产的比例 | 49. 94% | | 风险提示 | 本次担保中,部分被担保方的资产负债率 超过 70%。 | 1、2025年9月12日，控股子公司复星医药产业与哈比银行签订《综合授信合同》，由复星医药产 业向哈比银行申请等值2,500万美元的授信额度。同日，公司与哈比银行签订《保证合同一》，约定由 公司为复星医药产业于上述授信额度项下债务提供连带责任保证担保，保证期间为被担保债务项下的义 务和责任到期之日 ...

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (commercial name: Fuzhuoning) for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1: Drug Approval Details - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - FCN-437c is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights owned by the group [1] - The drug is characterized as an oral, potent, highly selective, and structurally novel small molecule [1] Group 2: Development Background - FCN-437c was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product portfolio and potential market opportunities [1]. Company Summary - The approved drug, Famotidine Injection, is a chemical medication independently developed by the group [1]. - The approved indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1]. Industry Summary - The approval of Famotidine Injection highlights the ongoing innovation and development within the pharmaceutical industry, particularly in the area of gastrointestinal treatments [1].

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a new indication for the drug FCN-437c (commercial name: Fuzhuoning), which is a CDK4/6 inhibitor for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1 - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - The drug is an innovative small molecule with independent intellectual property rights owned by the group [1] - FCN-437c was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product portfolio and potential market opportunities [1] Group 1: Product Approval - The drug, Famotidine Injection, is a self-developed chemical medication by the group [1] - The approved indication is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] - The approval highlights the company's commitment to addressing various causes of gastric and duodenal mucosal erosion and bleeding [1]

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Famotidine Injection [1] - The approved indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] - The drug is a chemically synthesized product developed independently by the company and its subsidiaries [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (commercial name: Fuzhuoning) for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1 - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - FCN-437c is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights owned by the group [1] - The drug is characterized as an oral, potent, highly selective, and structurally novel small molecule, and was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]

近日，上海复星医药控股子公司锦州奥鸿药业的法莫替丁注射液药品注册申请获国家药监局批准。该药 品为集团自主研发的化学药品，获批适应症为用于消化性溃疡所致上消化道出血等。截至2025年，集团 针对该药品累计研发投入若干万元（未审计）。IQVIACHPA数据显示，2024年法莫替丁注射剂在境内 销售额约13.77亿元。此次获批将丰富集团产品线，但药品上市销售受多种因素影响，存在不确定性， 提醒投资者注意风险。 ...

Company Overview - Fosun Pharma's stock price increased by 2.03% on September 15, reaching 32.16 CNY per share, with a trading volume of 8.01 billion CNY and a turnover rate of 1.19%, resulting in a total market capitalization of 858.81 billion CNY [1] - The company was established on May 31, 1995, and listed on August 7, 1998, with its main business focusing on drug manufacturing and research, covering medical devices, medical services, and pharmaceutical distribution and retail [1] Financial Performance - For the first half of 2025, Fosun Pharma reported a revenue of 19.514 billion CNY, a year-on-year decrease of 4.63%, while the net profit attributable to shareholders increased by 38.96% to 1.702 billion CNY [2] - The company has distributed a total of 12.593 billion CNY in dividends since its A-share listing, with 2.691 billion CNY distributed over the past three years [2] Stockholder Information - As of June 30, 2025, the number of shareholders decreased by 4.37% to 230,000, with an average of 0 circulating shares per shareholder [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 75.8807 million shares, an increase of 11.1938 million shares from the previous period [3]

公司公告汇总复星医药关于为控股子公司提供担保的进展公告 截至2025年9月12日收盘，复星医药(600196)报收于31.62元，上涨1.02%，换手率1.62%，成交量34.3万 手，成交额10.74亿元。 当日关注点 交易信息汇总资金流向 9月12日主力资金净流入5049.53万元，占总成交额3.37%；游资资金净流入3372.76万元，占总成交额 2.25%；散户资金净流出8422.29万元，占总成交额5.62%。 上海复星医药（集团）股份有限公司为控股子公司提供担保，涉及11家被担保方，包括复星医药产业、 复星实业、复星健康等。本次担保金额合计2,500万美元及人民币12.26亿元，均在前期预计额度内。担 保方式主要为连带责任保证或最高额连带责任保证，部分担保有反担保安排。截至2025年9月12日，集 团实际对外担保余额折合人民币约2,360,240万元，占2024年末经审计净资产的49.94%，无逾期担保。 本次担保已履行内部决策程序，无需另行审批。部分被担保方资产负债率超过70%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投 ...